Form 4: Agenus Executive Christine Klaskin Receives 2024 Performance Bonus in Company Stock

Christine M. Klaskin, Agenus Inc.'s Principal Financial Officer and Principal Accounting Officer, was awarded 15,782 shares of common stock as a 2024 performance bonus.

Summary

• Christine M. Klaskin, the Principal Financial Officer and Principal Accounting Officer (PFO & PAO) of Agenus Inc. (AGEN), reported an acquisition of company common stock.
• The transaction occurred on June 18, 2025, and involved the acquisition of 15,782 shares of Agenus Common Stock.
• The shares were acquired at a price of $4.47 per share, which was the fair market value on the issuance date.
• This stock issuance represents Ms. Klaskin's 2024 performance bonus award.
• The stock is fully vested on the date of issuance but is subject to a lockup restriction, with 100% of the award released on July 18, 2025.
• Following this transaction, Ms. Klaskin beneficially owns 23,478 shares of Agenus Common Stock.

Sentiment

Score: 6

Explanation: The filing reports a routine executive stock bonus, reflecting standard compensation practices and recognition of past performance, which is mildly positive for executive alignment but not a significant market driver.

Positives

• The award of stock as a performance bonus indicates recognition of the executive's contributions and performance during 2024.
• Equity compensation aligns the interests of the executive with those of the shareholders, as the executive's wealth is tied to the company's stock performance.

Risks

• The value of the stock award is subject to market fluctuations, meaning the actual realized value for the executive could be higher or lower than the issuance price.
• The lockup restriction until July 18, 2025, means the executive cannot sell these specific shares until that date, exposing them to potential market volatility during that period.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an executive compensation event.

Industry Context

This filing is a routine disclosure of executive compensation in the form of stock, common across publicly traded companies in all industries, including the biotechnology sector where Agenus operates. It reflects standard practices for aligning executive incentives with company performance.

Related Party Transactions

• The transaction involves the issuance of common stock by Agenus Inc. to Christine M. Klaskin, a company officer (PFO & PAO), as a performance bonus. This is a related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The issuance of new shares for compensation results in minor dilution, but also strengthens the alignment of executive interests with shareholder value through equity ownership.
• Employees: This transaction highlights the company's use of performance-based equity awards as part of its executive compensation framework.

Next Steps

• The lockup restriction on the awarded shares will be released on July 18, 2025, at which point the executive will have full control over the shares.

Key Dates

Keywords

Agenus, AGEN, Form 4, insider transaction, executive compensation, stock award, performance bonus, Christine Klaskin, equity compensation